Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Effect of Vasopressin and Methylprednisolone vs. Placebo on Long-Term Outcomes in Patients with In-Hospital Cardiac Arrest A Randomized Clinical Trial

Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  1. Clinical paper Functionality of registered automated external defibrillators

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  2. Modeling optimal AED placement to improve cardiac arrest survival: The challenge is implementation

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  3. Socio-demographic characteristics of basic life support course participants in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

Vis graf over relationer

OBJECTIVE: The primary results from the Vasopressin and Methylprednisolone for In-Hospital Cardiac Arrest (VAM-IHCA) trial have previously been reported. The objective of the current manuscript is to report long-term outcomes.

METHODS: The VAM-IHCA trial was a multicenter, randomized, double-blind, placebo-controlled trial conducted at ten hospitals in Denmark. Adult patients (age ≥ 18 years) were eligible for the trial if they had an in-hospital cardiac arrest and received at least one dose of epinephrine during resuscitation. The trial drugs consisted of 40 mg methylprednisolone (Solu-Medrol®, Pfizer) and 20 IU of vasopressin (Empressin®, Amomed Pharma GmbH) given as soon as possible after the first dose of epinephrine. This manuscript report outcomes at 6 months and 1 year including survival, survival with favorable neurological outcome, and health-related quality of life.

RESULTS: 501 patients were included in the analysis. At 1 year, 15 patients (6.3%) in the intervention group and 22 patients (8.3%) in the placebo group were alive corresponding to a risk ratio of 0.76 (95% CI, 0.41-1.41). A favorable neurologic outcome at 1 year, based on the Cerebral Performance Category score, was observed in 14 patients (5.9%) in the intervention group and 20 patients (7.6%) in the placebo group (risk ratio, 0.78 [95% CI, 0.41-1.49]. No differences existed between groups for favorable neurological outcome and health-related quality of life at either 6 months or 1 year.

CONCLUSIONS: Administration of vasopressin and methylprednisolone, compared with placebo, in patients with in-hospital cardiac arrest did not improve long-term outcomes in this trial.

OriginalsprogEngelsk
TidsskriftResuscitation
Vol/bind175
Sider (fra-til)67-71
Antal sider5
ISSN0300-9572
DOI
StatusUdgivet - jun. 2022

Bibliografisk note

Copyright © 2022 The Author(s). Published by Elsevier B.V. All rights reserved.

ID: 77730041